If not enough oxygen is administered to the infant, the apnea continues and the infant is unable proper recovery. In contrast, too much oxygen administered can lead to higher risk for retrolental fibroplasia and/or oxygen toxicity within the lungs. Continued dyspnea is a sign that Wilson-Mikity syndrome is still affecting the infant. Increased ventilation to allow proper respiration is then required. Patients in recovery are slowly taken off oxygen support and eventually are able to ventilate with minimal to no respiratory distress.There is a lack of research on the long-term effects of Wilson-Mikity into adulthood. Epidemiology
Around 75% of affected infants survive and are able to receive oxygen therapies and treatments to overcome this disease. In fatal cases, infants do not have noticeable or substantial respiratory recovery and can develop right-sided heart failure, ultimately leading to death. Patients that are not recovering will also continue to show signs of dyspnea, respiratory distress, and continued low body weight, heightening the risk of death. Infants that survive six months or longer have substantially better prognosis. See also
Infant respiratory distress syndrome
Bronchopulmonary dysplasia
Chronic obstructive pulmonary disease
Retrolental Fibroplasia
Chorioamnionitis

References
Further reading
Hoepker, A; Seear, M; Petrocheilou, A; Hayes D Jr; Nair, A; Deodhar, J; Kadam, S; OToole, J (Oct 2008). "Wilson-Mikity syndrome: updated diagnostic criteria based on nine cases and a review of the literature". Pediatric Pulmonology. 43 (10): 1004–12. doi:10.1002/ppul.20900. PMID 18781642. S2CID 25580427. Lehman, DH (October 1969). "The Wilson-Mikity syndrome. Case report and review of literature". California Medicine. 111 (4): 298–304. PMC 1503650. PMID 5388332. == External links ==
The FDA granted the approval of Oxlumo to Alnylam Pharmaceuticals, Inc.

Society and culture
Legal status
Lumasiran is available under the UK Early Access to Medicines Scheme (EAMS) as of July 2020.On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Oxlumo, intended for the treatment of primary hyperoxaluria type 1 (PH1). The applicant for this medicinal product is Alnylam Netherlands B.V.Lumasiran was approved for medical use in the European Union and in the United States in November 2020. References
External links
"Lumasiran". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT03681184 for "A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 (ILLUMINATE-A)" at ClinicalTrials.gov
Clinical trial number NCT03681184 for "A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B)" at ClinicalTrials.gov